Dexcom (Nasdaq:DXCM) today announced a collaboration to establish National Glucose Awareness Week from Sept. 23-29, 2024. The San Diego-based continuous glucose monitor (CGM) maker aims to close the glucose knowledge gap. In partnership with the nonprofit Beyond Type 2, Dexcom wants to encourage people to take action “to own their glucose health.” According to a […]
Featured
Ypsomed reports positive outcomes with automated insulin delivery for maternal health
Ypsomed reports positive outcomes from a large, randomized trial of its closed-loop insulin delivery technology during type 1 diabetes pregnancy. The Switzerland-based company’s AiDAPT study demonstrated that hybrid closed-loop therapy significantly improves maternal glycemic control. Pregnant women with type 1 diabetes used the automated insulin delivery system based on the CamDiab CamAPS FX algorithm in […]
Tandem wins clearance for t:slim X2 pump with Eli Lilly fast-acting insulin in Europe
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its t:slim X2 pump. The company can now offer its automated insulin delivery (AID) system with Eli Lilly’s Lyumjev (insulin lispro-aabc injection) ultra-rapid-acting insulin in Europe. Previously, the t:slim X2 pump had clearance for use with Humalog and […]
Phillips Medisize to buy inhaled drug delivery device maker Vectura from Philip Morris
Phillips Medisize parent company Molex announced that it agreed to acquire Vectura from a subsidiary of cigarette maker Philip Morris. Vectura designs and develops devices and formulations for inhaled drug delivery. Philip Morris paid $1.2 billion for the UK-based company in 2021 as part of its “Beyond Nicotine” effort to phase out cigarettes and develop […]
Class action suit targets Abbott FreeStyle Libre amid claims of data sharing
Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre platform. ClassAction.org first reported on the claims. The lawsuit alleges that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. Its FreeStyle.Abbott website provides educational tools for the continuous glucose […]
BD launches new prefillable syringe, expands platform capacity
BD (NYSE:BDX) announced today that it launched its Neopak XtraFlow glass prefillable syringe and expanded the capacity for the platform. The company said the launch and expansion aim to serve the growing market for biologic therapies. Neopak glass prefillable syringes address key development needs for biologic drugs, BD said in a news release. The syringes […]
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]
Aptar Pharma inks dev deal with Pulmotree for non-propellant liquid inhaler platform
Aptar Pharma announced that it entered into an exclusive collaboration agreement with Pulmotree to develop a liquid inhaler platform. The collaboration enables Aptar to lead the development and promotion of the Kolibri non-propellant liquid inhaler (NPLI) platform. Under the agreement, Aptar intends to provide Pulmotree with full support to accelerate growth. The company serves as […]
Vaxxas begins avian flu vaccine trial using high-density microarray delivery patch
Vaxxas announced that it began a multi-center Phase I clinical trial of a vaccine against avian flu using its high-density microarray patch. The company develops a vaccine patch based on its proprietary HD-MAP delivery technology. Vaxxas designed its HD-MAP technology to use an ultra-high-density array of micro projections, invisible to the human eye. Applied to […]
Orange Biomed to showcase microfluidic-based A1C test
Orange Biomed announced today that it plans to showcase its microfluidic-based A1C test at the 2024 Diabetes Technology Meeting. The company intends to present research for the device during the event’s Startup Showcase next month. It developed the pocket-sized, single-cell, micro-electro-mechanical A1C analysis device, agnostic to hemoglobin variants, to deliver faster, more reliable results for […]
